Southern Tail, Sweden, December 21, 2022 /PRNewswire/ — Anocca, a fully integrated cell therapy biotechnology company, today announced 25 million euros Venture debt funding from the European Investment Bank (EIB). This significant investment recognizes Anocca’s strength and high potential, as well as his innovative approach to developing T-cell therapies for cancer.
CEO and co-founder of Anoka Reagan Jarvis “We are delighted that the EIB has chosen to support us as we build a key piece of our advanced biotechnology capabilities and infrastructure. SwedenAnocca’s mission is to leverage its proprietary analytical and manufacturing platform to expand the clinical and commercial reach of cell therapies. This funding will help move our first generation of his T-cell immunotherapy into clinical trials in solid tumor indications during his 2024. “
Chairman of the Board of Annokka, Added by Hans Strawberg“This funding further validates Anocca’s cutting-edge and novel approach to immunotherapy. We welcome EIB to our group of committed investors as we continue to build Europe’s leading therapeutics: a biotechnology company with the potential to transform the treatment of serious diseases. We are a technology company.”
Paolo Gentiloni, Economic Commissioner of the European Commission, said: Sweden in life sciences. It is also an important contribution to the development of cutting-edge technologies to help fight cancer. European Defeat the Gun Plan. Our research and development efforts require significant and sustained investments to ensure we deliver on our promises for the future. InvestEU helps build this bright future by giving innovative companies access to the funding they need to grow and continue to innovate. “
EIB Vice President Thomas Estros said: 25 million euros EIB venture debt support for Swedish biotech company Anocca. Ultimately, our funding will help accelerate clinical development to provide patients with access to innovative therapies in areas of high unmet medical need.This support confirms and boosts his EIB’s role as a leading investor in innovation and life sciences European Competitiveness and role as a research powerhouse. “
Anocca uses its advanced technology to design next-generation T-cell immunotherapies to treat solid tumors with unmatched precision, speed and scale. The company is building a library of new His T-cell immunotherapies targeting particularly hard-to-treat cancers, which are expected to enter clinical trials in 2024. Alongside oncology, the company’s proprietary technologies are applied to the development of vaccines and therapeutics for autoimmune diseases.
Anocca has a fully integrated research and development infrastructure supported by bespoke advanced software solutions and in-house clinical manufacturing and process development facilities. This unique discovery platform uses programmable human cells to generate a broad pipeline of targets and T-cell receptors with blockbuster potential as cell therapy products.
Founded in 2014, Anocca is led by an experienced management team. 100 million euros It is funded by leading Nordic investors. In 2022, the company will 25 million euros It is funded by the European Investment Bank. Annokka’s team of over 90 employees operates from its state-of-the-art R&D and manufacturing facility in Sodertalje. SwedenFind out more about Anokka here. www.anocca.com and follow us LinkedIn.
About the European Investment Bank
See www.eib.org/en/ for more information.
European Investment Bank (EIB) is a European Union bank owned by EU27 member states that finances projects in four priority areas: Infrastructure, Innovation, Climate and Environment, and Small and Medium Enterprises (SMEs). With operations in approximately 160 countries, it is the world’s largest multilateral financier of climate change projects. The bank provides long-term financing for economically sustainable investments to contribute to the political goals of the European Union. EIB’s Climate Bank Roadmap 2025 express willingness to support 1 trillion euros Investing in climate action and environmental sustainability over the decade to 2030.
View original content: https://www.prnewswire.com/news-releases/anocca-secures-eur-25-million-from-the-european-investment-bank-eib-to-support-clinical-development- of-next-generation T-cell therapy-for-cancer-301707558.html